TFCM
INDP icon

Taylor Frigon Capital Management’s Indaptus Therapeutics INDP Stock Holding History

Taylor Frigon Capital Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-185
Closed -$302K – 88
2019
Q3 		$302K Buy
+185
New +$551K 0.22% 84

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Taylor Frigon Capital Management's INDP Position: Q4 2019 in Review

Taylor Frigon Capital Management sold out of Indaptus Therapeutics (INDP) in Q4 2019, closing a stake of 185 shares — an estimated $302K sold.

Taylor Frigon Capital Management first reported a position in INDP in Q3 2019 and held it in 1 quarter. The position peaked at $302K in Q3 2019. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • Taylor Frigon Capital Management reported no remaining Indaptus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Taylor Frigon Capital Management sold 185 Indaptus Therapeutics shares in Q4 2019, an estimated $302K.
  • Taylor Frigon Capital Management first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 1 quarter.
  • Taylor Frigon Capital Management's Indaptus Therapeutics position peaked at $302K in Q3 2019.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on Taylor Frigon Capital Management's 13F filing for Q4 2019, filed 24 Jan 2020.